{"disease":{"id":"polypoidal-choroidal-vasculopathy","name":"polypoidal choroidal vasculopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03128463","title":"Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Xun Xu","has_results":false},{"nct_id":"NCT05639660","title":"Clinical Implication of Aflibercept in PCV Treatment in China","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05229237","title":"Conbercept for Polypoidal Choroidal Vasculopathy（START Study）","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01846273","title":"Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04101604","title":"Biomarkers of Common Eye Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07365371","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05666804","title":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05662943","title":"Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV","phase":"","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false},{"nct_id":"NCT03929731","title":"Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Singapore National Eye Centre","has_results":false},{"nct_id":"NCT03941587","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Singapore National Eye Centre","has_results":false},{"nct_id":"NCT03459144","title":"Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04714242","title":"OCTA and Polypoidal Choroidal Vasculopathy","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03117634","title":"An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Singapore National Eye Centre","has_results":true},{"nct_id":"NCT02495181","title":"Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Association for Innovation and Biomedical Research on Light and Image","has_results":false},{"nct_id":"NCT02860858","title":"Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Department of Medical Services Ministry of Public Health of Thailand","has_results":false},{"nct_id":"NCT07461441","title":"Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false},{"nct_id":"NCT02769169","title":"Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02397954","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Ophthotech Corporation","has_results":true}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}